Pulmonary Hypertension Educational Information by Dr. Jeremy Feldman

Home

Pulmonary Hypertension

Pulmonary Hypertension RN is an educational resource for patients, caregivers, friends, and family members interested in learning about PAH. It is an exciting time for the pulmonary hypertension community because new pathways to treat the disease and new treatments are being researched and approved by the FDA (Food and Drug Administration). Prior to 1996, there were no specific therapies approved to treat PAH. Without treatment many pulmonary hypertension patients experienced rapid progression of their disease and eventually death. Since then, the FDA has approved several treatments to slow down the progression of the disease and improve quality of life. Unfortunately, due to a lack of awareness about PAH patients continue to be misdiagnosed or not treated.

Jeremy Feldman, MD has devoted his career to treating patients with pulmonary arterial hypertension and has developed this resource to help educate the community and provide the most up to date information on treating pulmonary arterial hypertension.

This site provides information on:

All information is edited by an MD and RN (Registered Nurse) specializing in pulmonary hypertension.

Why Abortion Matters to PAH Patients

By Dr. Jeremy Feldman

Across America a woman’s right to terminate an unwanted pregnancy is under threat. Without diving into politics or religion I want to impress on the PAH community why this may spell disaster for our PAH patients.

Aerovate and Inhaled Imatinib

By Dr. Jeremy Feldman

You can think of tyrosine kinases as critical switches in cells that turn on and off critical pathways. Too much of an “on” signal leads to dysregulated cell proliferation and growth—such as seen in the pulmonary arteries of PAH patients

Sotatercept for Pulmonary Arterial Hypertension

By Dr. Jeremy Feldman

For the past 30 years, all our pulmonary arterial hypertension medications were described as vasodilators: First prostanoids (epoprostenol), then endothelin receptor antagonists (bosentan, ambrisentan, macitentan) and PDE5 inhibitors (sildenafil and tadalafil). These medications work through different mechanism but all lead to the vasodilation or relaxation of blood vessels in the lungs. Unfortunately, they all share a similar side effect profile: headaches, flushing, nasal congestion, diarrhea. Progress with these three families of medications has been noteworthy.

Back in Action

By Dr. Jeremy Feldman

Please forgive the hiatus in posting new content. When I am not caring for pulmonary hypertension and pulmonary fibrosis patients I am also an intensive care unit doctor and have been inundated caring for many thousands of patients with severe COVID. My team and I have cared for well over 8,000 patients with severe COVID during the past two years.

Over the past year it has become crystal clear that vaccines work. The overwhelming majority of patients dying from COVID are unvaccinated and unboosted. In the absence of underlying diseases that impair the immune system or medications that suppress the immune system, the vaccines provide robust protection against getting critically ill or dying from COVID.

Home